Rivaroxaban: Overview of core drugs and applications in anticoagulation therapy

Rivaroxaban is a new oral anticoagulant that exerts anti-thrombotic effects by specifically inhibiting factor Its advantage is that it does not require routine monitoring of coagulation function, the dose is fixed, and it is highly safe. The main contents include:Mechanism of action,Indications and usage,Adverse reactions and contraindications,Manufacturer and product information. The following will expand one by one.

Mechanism of action and clinical value

Rivaroxaban blocks the key link in thrombosis by directly inhibiting factor Xa in the coagulation cascade. Compared with the traditional anticoagulant warfarin, it has a rapid onset of action, fewer drug interactions, and is not affected by diet. Clinical studies have shown that rivaroxaban has significant efficacy in reducing the risk of stroke in patients with atrial fibrillation (RE-LY trial), while reducing the risk of major bleeding. Patients should strictly follow the doctor's instructions and avoid adjusting the dosage on their own.

Indications and standardized medication

Rivaroxaban is approved for:①Acute treatment and long-term prevention of DVT/PE;②Stroke prevention in nonvalvular atrial fibrillation;③Thromboprophylaxis after orthopedic surgery (eg, hip/knee replacement). The conventional dose is 10-20 mg/day, and needs to be adjusted in patients with renal insufficiency. During medication, you need to be alert to the risk of bleeding and avoid using it in combination with NSAIDs. Not allowed for special groups (pregnant women, children).

Adverse reactions and risk management

Common adverse reactions includeBleeding gums,epistaxisandgastrointestinal bleeding, intracranial hemorrhage may occur in severe cases. The patient's bleeding risk (such as HAS-BLED score) needs to be assessed before medication, and renal function should be monitored regularly. If bleeding occurs, consider usingReversal agent Andexanet alfa(Not yet popular in China). In addition, if you miss a dose, you should take it according to the instructions to avoid double dose.

Summary and production information

As an important choice for anticoagulant treatment, rivaroxaban balances efficacy and safety, but it requires individualized medication. At present, major domestic manufacturers includeBayer (original drug, trade name: Xarelto)and many generic drug companies (such as Chia Tai Tianqing and Hansoh Pharmaceuticals). Patients should use it under the guidance of a doctor and pay attention to the results of the drug consistency evaluation.

Quote source:

1. "China Guidelines for the Prevention and Treatment of Thrombotic Diseases" (2018 Edition)
2. European Society of Cardiology (ESC) Guidelines for the Management of Atrial Fibrillation (2020)
3. RE-LY clinical trial data (New England Journal of Medicine, 2009)
4. National Medical Products Administration (NMPA) drug approval information